Introduction
============

The incidence of double primary malignancy has not been rare at all \[[@b1-IJCP-07-066]-[@b4-IJCP-07-066]\]. One of the earliest statistical analyses of double primary malignancies has carried out by Bugher in 1934, which has derived an equation for the probability of death from cancer during a specified period of age with a coincidental second malignancy \[[@b5-IJCP-07-066]\].

The presence of dysplastic changes in the second primary site strongly has suggested a new primary. The aim of this study was the report of our observation about increasing incidence of multiple primary malignancies. Further, with recently treatment modalities, cancer patients have survived much longer to be able to develop metachronous new primary, which might partly related to the treatment of earlier malignancy. It was also obvious, which with the recently improved diagnostic modalities such as Positron Emission Tomography (PET), that amounts of picking up indolent tumors have increased contributing, further to the obvious increase of multiple primary malignancies incidence \[[@b6-IJCP-07-066], [@b7-IJCP-07-066]\].

Double primary malignancies could be divided into two categories, depending on the interval between tumor diagnoses \[[@b8-IJCP-07-066]\]. Synchronous malignancies were second tumors have been occurring either simultaneously, or within 6 months after the first malignancy while metachronous malignancies were secondary tumors that have developed after 6 months, or even more than that from the first malignancy.

The criteria have used for the diagnosis of double primary malignancies, have primarily given by Warren and Gates ([Table 1](#t1-IJCP-07-066){ref-type="table"}) and refined later \[[@b9-IJCP-07-066]-[@b12-IJCP-07-066]\].

Materials and Methods
=====================

The study was a retrospective collection of the prospective data from the hospital database of patients either presenting with histologically proven synchronous or metachronous double primaries as defined by above criteria over a 4 years period, from 2009 to 2012. The time interval to differentiate between synchronous or metachronous has taken as 6 months as reported by several authors \[[@b8-IJCP-07-066], [@b12-IJCP-07-066], [@b13-IJCP-07-066]\].

The inclusion criteria of patients in this study were the presence of at least two neoplastic locations, that confirmed by histopathological examination, with distinct histopathology in the two locations. We have excluded patients without a clear histopathological confirmation of each tumor, and then also the patients whom the second tumor has suspected to be a metastasis of the first location.

Various details like patient age at time of each tumor diagnosis, sex, synchronous or metachronous, site of origin, diagnosis method, histology, detection clinical stage, and treatment regimen have been recorded.

Results
=======

More than a 4 years period, between 2009 and 2012, total 23,260 cancer patients have registered to Regional Cancer Institute, out of which 41 cases (0.18%) of multiple primary malignancies have observed.

Out of 41 cases, 8 were synchronous (19.51%) and 33 were metachronous (80.49%). Six months (180 days) has considered as the maximum period for the synchronous tumors occurrence. The occurrence interval of metachronous tumors have ranged from 1 to 26 years, with an average of 5.08 years for the entire group. Out of 41 patients, 25 (60.97%) were females and 16 (39.03%) were males.

The median age at the primary malignancy diagnosis, was 48 years (range 27-65 years). The most common site of primary tumor was head and neck (14 cases; 34.15%) followed by gynecological cancers (9 cases; 21.95%), breast (7 cases; 17.07%), lung cancer (2 cases; 4.9%), esophageal cancer (3 cases; 7.3%) and then other tumors (6 cases; 14.6%) ([Figure 1](#f1-IJCP-07-066){ref-type="fig"}). The age range for the second primary tumor was between the 31-71 years. Among the second malignancy, the most common site was breast (9 cases; 21.95%) and gastrointestinal tract (9 cases; 21.95%) followed by lung (7 cases; 17.07%) and gynecological cancers (5 cases; 12.20%) ([Figure 2](#f2-IJCP-07-066){ref-type="fig"}).

Out of the total number of cases with double location, 14 tumors (34.15%) have belonged to the breast, out of which 5 (12.20%) have represented first locations and 7 (17.07%) were second locations. Both locations belonged to the breast in 2 patients (4.9%). In 5 cases (12.20%), we have observed association of breast-cervix, and in 6 cases (14.63%), there were association between the lung-head & neck cancers.

Discussion
==========

Among the total cancer patients who were admitted to the Regional Cancer Institute between 2009 and 2012, female to male ratio was 0.8:1, while the analysis of patients with double neoplastic locations have revealed a 1.56:1 female-male ratio; that has reversed. Most of the patients belonged to the 5th to 6th age decades (27 of 41; 65.85%). Most diagnosed tumors were metachronous in comparison to synchronous (33 compared with 8).

With regard to tumor stage and treatment, there was no difference between first primary and second primary malignancies of same anatomical sites. However, primary and secondary tumors have tended to be in an advanced stage and the treatment, depending on the location, involved surgery, radiotherapy and chemotherapy. The advanced stage of secondary malignancies was unusual, in comparison to other studies. It should explained either by the low compliance of patients to follow-up, or by their tendency to neglect symptoms. The results have underscored the importance of a good communication between patients and doctors, whereby the doctors should give warnings regarding the risk of developing secondary malignancies after the primary treatment, and then also about the occurrence of any new symptoms.

Although the responsible mechanisms for the multiple primary cancers appearance have not been fully explained, but among the most frequent factors that have involved, we could mention: the genetic susceptibility, the immune system of patients, and the intensive exposure to carcinogens including chemo- and/or radiotherapy used in the treatment of tumors.

A secondary malignancy could be defined as a new cancer that has occurred as a result of previous treatment with radiation or chemotherapy. Depending on the schedule of treatment, the most common secondary cancers were skin cancer, breast cancer, acute leukemia, colorectal, lung and stomach cancer, the risk of second cancer developing have been 10% at 20 years and 26% at 30 years after the Hodgkin disease treatment, \[[@b14-IJCP-07-066]\] and 3.8 % at 10 years versus 7% at 15 years for patients receiving a doxorubicin-based regimen for breast cancer \[[@b15-IJCP-07-066]\].

Not only Genetic susceptibility, but also the carcinogenic effects of radio/chemotherapy have been largely proposed for the secondary malignancies development. First, it has known, that people with a cancer family would inherit genetic cancer susceptibility as a risk factor, and then moreover, patients whom have treated, and the survivors of earlier cancers with genetic susceptibility, all have an increased risk of multiple primary malignancies. In addition, the treatment used for the first malignancy has resulted in damage to specific regions of DNA with chromosome rearrangement or loss, responsible for tumorigenesis \[[@b16-IJCP-07-066]\]. The new technologies available could analyze various genetic changes such as punctiform mutations, loss of heterozygosity or genetic instability. Microsatellite instability (MSI) has been noticed that occur more frequently in cases of multiple primary malignancies than in sporadic cancers \[[@b17-IJCP-07-066]\]. The percentage of MSI tumors was similar in patients with synchronous or colorectal metachronous tumors. The mechanisms such as trigger microsatellite instability have differed in mentioned two categories.

Patients with Head and Neck Squamous Cell Cancer (HNSCC) have known for 36% cumulative life time risk of developing second primary malignancy over 20 years \[[@b18-IJCP-07-066]\]. This has attributed to field carcinogenesis related to exposure to common risk factors like tobacco chewing, smoking and alcohol consumption \[[@b12-IJCP-07-066], [@b18-IJCP-07-066]\]. Also In our study head and neck cancers were the most common group to harbor of develops a new primary (10 of 33 cases). Among the head and neck cancer survivors, the cases whom have developed lung cancer were 50% (5 of 10 cases). As a part of preventive strategy, the patients particularly with HNSCC should be encouraged to stop use of alcohol and tobacco in any form, adopt healthy diet and exercise regularly. At present there is no evidence to recommend use of chemo preventive agents such as beta carotenoids and antioxidants in the prevention of second primary malignancies \[[@b19-IJCP-07-066]\].

The possibility of multiple primary malignancies existence should always be considered during pretreatment evaluation. Screening procedures were especially useful for the early detection of associated tumors, preferably before clinical manifestations occurrence.

There were some evidences that screening would improve outcomes among patients who might develop second malignancies, although the data were limited. The optimal screening modalities and strategies for reducing mortality from second malignancies remained to be defined for most tumor sites \[[@b20-IJCP-07-066]\].

The early diagnosis of secondary malignancies should not be neglected in patients treated for a primary malignancy, especially when the long clinical period before the diagnosis of subsequent tumors has been taken for management. With careful monitoring, secondary tumors could be detected earlier, and, with appropriate intervention, might be better managed, without compromising survival.

Our data could guide oncologists towards a closer follow-up strategy in the management of patients treated for common tumors.

Conclusion
----------

In conclusion, second primary malignancy was not uncommon, could occur synchronously or metachronously. After the recently diagnostic and staging modalities as well as progress in the management of common cancer, the detection of second primary malignancy has increased. A strong clinical suspicion and thorough evaluation would pass a long road in the management of these tumors. Most of the operable synchronously occurring second primary malignancy could be resected in single stage. A regular follow up could detect most of the metachronous second primary malignancies at an early stage.
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###### 

Warren and Gates Criteria for Diagnosis of Double Primary Malignancies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. Histological confirmation of malignancy in both the index and secondary tumors.
  2\. There should be at least 2 cm of normal mucosa between the tumors. If the tumors are in the same location, then they should be separated in time by at least five years.
  3\. Probability of one being the metastasis of the other must be excluded.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of synchronous double malignancies

  S. No.   Age (years)   Sex   Primary site          Histopathology                                      Treatment                                                 Second site             Histopathology                                      Treatment
  -------- ------------- ----- --------------------- --------------------------------------------------- --------------------------------------------------------- ----------------------- --------------------------------------------------- ---------------------------------------------------------------------
  01       45            F     Cervix                Moderately differentiated Squamous cell carcinoma   Chemoradiation                                            Right breast            Invasive ductal carcinoma                           Neoadjuvant chemotherapy, Modified radical mastectomy, Radiotherapy
  02       37            F     Left gluteal region   Leiomyosarcoma                                      Surgery                                                   Right breast            Invasive ductal carcinoma                           Modified radical mastectomy, Chemotherapy, Radiotherapy
  03       55            F     Thyroid               Papillary carcinoma                                 Total thyroidectomy                                       Oesophagus              Moderately differentiated Squamous cell carcinoma   Surgery
  04       65            M     Lung                  Squamous cell carcinoma                             Chemotherapy, Radiotherapy                                Prostate                Adenocarcinoma                                      Surgery
  05       27            F     Brain                 Cerebello pontine angle tumor                       Surgery, Radiotherapy                                     Breast                  Invasive ductal carcinoma                           Neoadjuvant chemotherapy, Modified radical mastectomy, Radiotherapy
  06       39            F     Breast                Invasive ductal carcinoma                           Modified radical mastectomy, Chemotherapy, Radiotherapy   Urinary bladder         Transitional cell carcinoma                         Surgery
  07       53            M     Pyriform fossa        Squamous cell carcinoma                             Chemoradiation                                            Oesophagus middle 3rd   Squamous cell carcinoma                             Chemoradiation
  08       64            M     Tongue                Squamous cell carcinoma                             Surgery                                                   Buccal mucosa           Well differentiated Squamous cell carcinoma         Surgery, Radiotherapy

###### 

Summary of metachronous double malignancies

  S. No.   Age at primary malignancy (years)   Sex   Primary site          Histopathology                                      Treatment                                                    Second site       Histopathology                  Time interval (years)   Treatment
  -------- ----------------------------------- ----- --------------------- --------------------------------------------------- ------------------------------------------------------------ ----------------- ------------------------------- ----------------------- ---------------------------------------------------------------------
  01       45                                  M     Lung                  Squamous cell carcinoma                             Chemotherapy, Radiotherapy                                   Ascending colon   Adenocarcinoma                  2.5                     Surgery, Chemotherapy
  02       62                                  M     Larynx                Squamous cell carcinoma                             Radiotherapy                                                 Kidney            Renal cell carcinoma            2                       Surgery
  03       55                                  F     Right Breast          Invasive ductal carcinoma                           Surgery, Chemotherapy, Radiotherapy                          Vulva             Squamous cell carcinoma         7                       Surgery, Radiotherapy
  04       52                                  M     Larynx                Squamous cell carcinoma                             Surgery                                                      Gall bladder      Adenocarcinoma                  1                       Surgery
  05       41                                  M     Hypopharynx           Squamous cell carcinoma                             Chemoradiation                                               Lung              Squamous cell carcinoma         1                       Chemoradiation
  06       58                                  F     Urinary bladder       Transitional cell carcinoma                         Surgery, Radiotherapy                                        Gall bladder      Adenocarcinoma                  2                       Surgery
  07       46                                  F     Right Breast          Invasive ductal carcinoma                           Surgery, Chemotherapy, Radiotherapy                          Cervix            Squamous cell carcinoma         2                       Chemoradiation
  08       45                                  F     Cervix                Moderately differentiated Squamous cell carcinoma   Surgery, Radiotherapy                                        Right breast      Infiltrative ductal carcinoma   3                       Surgery, Chemotherapy, Radiotherapy
  09       50                                  F     Cervix                Squamous cell carcinoma                             Chemoradiation                                               Lung              Squamous cell carcinoma         2                       Chemotherapy, Radiotherapy
  10       45                                  M     Right testis          Seminoma                                            Surgery, Chemotherapy                                        Base of tongue    Squamous cell carcinoma         2                       Chemoradiation
  11       40                                  F     Cervix                Squamous cell carcinoma                             Chemoradiation                                               Ovary             Adenocarcinoma                  1                       Surgery, Chemotherapy
  12       44                                  F     Cervix                Squamous cell carcinoma                             Chemoradiation                                               Ovary             Adenocarcinoma                  26                      Surgery, Chemotherapy
  13       57                                  M     Pyriform fossa        Squamous cell carcinoma                             Radiotherapy                                                 Hard palate       Squamous cell carcinoma         14                      Chemoradiation
  14       57                                  M     Base of tongue        Moderately differentiated Squamous cell carcinoma   Chemoradiation                                               Lung              Squamous cell carcinoma         3                       Chemotherapy, Radiotherapy
  15       42                                  F     Uterus                Adenocarcinoma                                      Surgery, Radiotherapy                                        Sigmoid colon     Adenocarcinoma                  2                       Chemotherapy
  16       27                                  F     Oesophagus            Moderately differentiated Squamous cell carcinoma   Chemotherapy, Radiotherapy                                   Leukaemia         AML                             4                       Chemotherapy
  17       65                                  F     Cervix                Squamous cell carcinoma                             Chemoradiation                                               Breast            Invasive ductal carcinoma       2.5                     Neoadjuvant chemotherapy, Modified radical mastectomy, Radiotherapy
  18       60                                  F     Left breast           Infiltrative ductal carcinoma                       Surgery, Chemotherapy, Radiotherapy                          Oesophagus        Squamous cell carcinoma         6                       Chemotherapy
  19       35                                  F     Right breast          Invasive ductal carcinoma                           Chemotherapy, Surgery, Radiotherapy                          Parotid           Mucoepidermoid carcinoma        6                       Surgery
  20       53                                  F     Gall bladder          Adenocarcinoma                                      Surgery                                                      Breast            Invasive ductal carcinoma       4                       Neoadjuvant chemotherapy, Modified radical mastectomy, Radiotherapy
  21       50                                  M     Base of tongue        Squamous cell carcinoma                             Chemoradiation                                               Lung              Non-small cell carcinoma        4                       Chemotherapy
  22       60                                  M     Right buccal mucosa   Moderately differentiated Squamous cell carcinoma   Surgery, Chemoradiation                                      Lung              Squamous cell carcinoma         10                      Chemotherapy
  23       27                                  F     Oesophagus            Squamous cell carcinoma                             Chemotherapy                                                 Brain             Astrocytoma WHO grade II        1                       Surgery, Radiotherapy
  24       50                                  F     Cervix                Squamous cell carcinoma                             Surgery, Radiotherapy                                        Right breast      Invasive ductal carcinoma       13                      Surgery, Chemotherapy, Radiotherapy
  25       50                                  M     Larynx                Squamous cell carcinoma                             Radiotherapy                                                 Lung              Adenocarcinoma                  3.5                     Chemotherapy
  26       37                                  F     Right breast          Papillary ductal carcinoma                          Neoadjuvant chemotherapy, Surgery, Radiotherapy, Tamoxifen   Left breast       Invasive ductal carcinoma       10                      Surgery, Chemotherapy, Radiotherapy
  27       48                                  M     Upper lip             Squamous cell carcinoma                             Surgery                                                      Oesophagus        Squamous cell carcinoma         4                       Chemoradiation
  28       29                                  F     Ovary                 Sex cord stromal tumor                              Surgery, Chemotherapy                                        Cervix            Squamous cell carcinoma         8                       Chemoradiation
  29       48                                  F     Right breast          Invasive ductal carcinoma                           Chemotherapy, Surgery, Radiotherapy                          Left Breast       Invasive ductal carcinoma       4                       Chemotherapy, Modified radical mastectomy, Radiotherapy
  30       46                                  F     Gall bladder          Adenocarcinoma                                      Surgery                                                      Stomach           Adenocarcinoma                  2                       Surgery
  31       64                                  M     Oesophagus            Squamous cell carcinoma                             Radiotherapy                                                 Prostate          Adenocarcinoma                  5                       Surgery
  32       41                                  F     Buccal mucosa         Squamous cell carcinoma                             Surgery, Radiotherapy                                        Thyroid           Papillary carcinoma             8                       Surgery
  33       57                                  M     Nasal cavity          Squamous cell carcinoma                             Radiotherapy                                                 Lung              Squamous cell carcinoma         2                       Chemotherapy, Radiotherapy
